vimarsana.com

Prnewswire Zyversa Therapeutics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerDivision of nephrologyUniversity of torontoFounder of orphan solutionsProducts developmentDepartment of pediatrics at university michiganKatz family division of nephrology

ZyVersa Therapeutics Appoints Three New Board Members

/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs.

Robertg finizioKatrin rupallaGregoryg freitagAmbrx biopharmaStephenc gloverDaniel oconnorJames sapirsteinEnochian biosciencesLectec corporationAxogen incPfizer incCompanies section governing boardContravir pharmaceuticalsGilead sciencesPrnewswire zyversa therapeutics incGuidant corporation

ZyVersa Therapeutics Appoints Three New Board Members

New appointments bring expertise and proven leadership to ZyVersa to support advancement and development of VAR 200 for renal disease, and IC 100 .

Robertg finizioKatrin rupallaGregoryg freitagAmbrx biopharmaStephenc gloverDaniel oconnorJames sapirsteinEnochian biosciencesLectec corporationAxogen incPfizer incCompanies section governing boardContravir pharmaceuticalsPrnewsfoto variant pharmaceuticals incGilead sciencesPrnewswire zyversa therapeutics inc

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerDivision of nephrologyUniversity of torontoFounder of orphan solutionsProducts developmentDepartment of pediatrics at university michiganKatz family division of nephrology

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersa s distinguished group of Scientific AdvisorsVAR 200 is a phase 2a-ready cholesterol e.

United statesAlessia fornoniDanielc cattranSharong adlerFernandoc fervenzaDebbies gipsonStephenc gloverPabloa guzmanPablo guzmanMarlene haffnerDivision of nephrologyUniversity of torontoFounder of orphan solutionsProducts developmentDepartment of pediatrics at university michiganKatz family division of nephrology

vimarsana © 2020. All Rights Reserved.